Table 3.
Pre-treatment demographics, oncological data, and motor status of patients with central metastasis, based on the treatment modalities, namely, MRS or SRS/SRT
| Overall | MRS | SRT/SRS | p | |
|---|---|---|---|---|
| Treatments | 68 | 27 | 41 | |
| Patients (n) | 64 | 27 | 37 | |
| Females (%) | 52% | 52% | 52% | n.s. |
| Age (years) | 59.5 | 60 | 59 | n.s. |
| RPA | 1.83 | 1.85 | 1.81 | n.s |
| KPI pre-operative * | 78 | 80 | 78 | n.s |
| Tumor-Volume (cm3) * | 7.2 | 10.5 | 4.9 | <0.02 |
| Patients with Hemiparesis | 36 | 24 | 12 | <0.005 |
| Muscle strength (BMRC)*: | ||||
| Arm | 4.3 | 3.7 | 4.7 | <0.008 |
| Leg | 4.6 | 4.3 | 4.8 | <0.0005 |
| NSCLC | 43% | 44.4% | 42.4% | n.s |
| Mamma-Ca | 14.5% | 18.5% | 11.9% | n.s. |
| Melanoma | 13% | 18.5% | 9.5% | n.s. |
| Renal Cell Ca | 5.8% | 0% | 9.5% | n.s. |
| CUP | 5.8% | 0% | 9.5% | n.s. |
| SCLC | 4.3% | 0% | 7.1% | n.s |
| Germ Cell Ca | 4.3% | 7.4% | 2.4% | n.s. |
| Gastrointestinal Ca | 4.3% | 3.7% | 4.8% | n.s. |
| Urothelial Cell Ca | 2.9% | 3.7% | 2.4% | n.s. |
| Sarcoma | 1.4% | 3.7% | 0% | n.s. |
SRT/SRS Stereotactic radiotherapy or radiosurgery, MRS Microsurgery, KPI Karnofsky performance index, RPA Recursive partitioning analysis, BMRC British Medical Research Council, NSCLC Non-small cell lung cancer, SCLC small cell lung cancer, Ca Carcinoma, CUP: Carcinoma of unknown primary, n.s not significant
* mean value